• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Bristol-Myers, AbbVie eye approval of myeloma drug

Bristol-Myers, AbbVie eye approval of myeloma drug

September 1, 2015
CenterWatch Staff

A new blood cancer drug from Bristol-Myers Squibb and AbbVie is speeding toward FDA approval, winning a priority review to treat multiple myeloma.

The antibody, called elotuzumab, is designed to focus the immune system’s attention on a protein called SLAMF7, which is expressed by tumor cells that might otherwise go unnoticed by the body’s natural defenses. With the priority review tag, the FDA pledges to give the two companies a final decision within six months, shortening the standard 10-month time frame.

Bristol-Myers and AbbVie plan to market elotuzumab as Empliciti, with a goal of using the drug as part of a cocktail for multiple myeloma patients who already have undergone one or more rounds of therapy. In Phase III results submitted to the FDA, a combination of elotuzumab, Celgene’s Revlimid and generic dexamethasone beat out the two older drugs on their own. The antibody garnered the FDA’s all-important breakthrough-therapy designation in 2014 based on positive Phase II data, guaranteeing its makers access to top-level agency officials throughout the development process.

Elotuzumab has taken a long path to FDA review. In 2008, Bristol-Myers licensed the drug from PDL BioPharma for $30 million up front, shortly before PDL spun off its biotech division into a firm called Facet Biotech. Abbott Laboratories purchased Facet for $450 million five years ago and then spun off its proprietary pharma business into AbbVie in 2013, effectively partnering the new firm with Bristol-Myers at the same time. The two have now joined forces to strengthen their respective oncology portfolios.

Success with elotuzumab would follow New York-based Bristol-Myers’ well-documented work with Opdivo, an antibody that mobilizes an immune system attack on cancer by blocking the protein PD-1 and leads a new pack of oncology treatments that is positioned to bring in $30 billion or more at its peak.

Meanwhile, Illinois-based AbbVie is hoping to build out a franchise in blood cancer after spending $21 billion on Pharmacyclics and a 50% share of Imbruvica, its chronic lymphocytic leukemia (CLL) treatment. Alongside partner Roche, AbbVie is moving forward with the Phase III CLL treatment venetoclax, hoping it can piece together a winning combination.

Upcoming Events

  • 17May

    Three Data Trends to Consider Now When Developing Your Decentralized Clinical Trial Strategy

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing